Blueprint Medicines: cross-border access for the specialty portfolio

Quick orientation

Blueprint Medicines Corporation is a US precision-medicine biotechnology company headquartered in Cambridge, Massachusetts, focused on genomically defined cancers and systemic mastocytosis. Blueprint's core platform identifies kinase-driven diseases and develops selective small-molecule inhibitors against them. The company trades on NASDAQ as BPMC. FDA approval scale includes two marketed products in the United States and an active development pipeline covering further mast cell, oncology, and immune indications. Blueprint's signature commercial asset, Ayvakit, has become the foundational treatment for advanced and indolent systemic mastocytosis, and the company is investing in expansion of the mastocytosis franchise as well as adjacent immune-disease targets where mast cell biology is implicated.

Blueprint Medicines portfolio in cross-border NPP scope

Ayvakit (avapritinib) is an FDA-approved oral kinase inhibitor with two distinct indication families: gastrointestinal stromal tumors (GIST) with PDGFRA exon 18 mutations (FDA approved January 2020), and systemic mastocytosis - advanced systemic mastocytosis in 2021 and indolent systemic mastocytosis in May 2023. The indolent systemic mastocytosis approval was a landmark moment for the field because indolent SM had no previously approved targeted therapy and patients had been managed only with symptom-directed antihistamines, mast cell stabilizers, and other supportive measures. US list pricing for Ayvakit is approximately US$32,000 per month, with weight-independent oral dosing. The product is supplied in capsules and is shipped at ambient temperature.

Gavreto (pralsetinib) is a selective RET inhibitor approved by the FDA for RET fusion-positive non-small cell lung cancer and RET-altered thyroid cancers. Following commercialisation restructuring, Gavreto is now commercialised by Roche/Genentech in the United States; Reserve Meds coordinates Gavreto via the Genentech manufacturer page for US-sourced inventory.

Blueprint's pipeline includes elenestinib (BLU-263) for systemic mastocytosis as a next-generation candidate, BLU-808 for chronic spontaneous urticaria and other mast cell-mediated diseases, and several earlier-stage kinase candidates. These are investigational and not in NPP scope.

Why patients route through cross-border NPP

Indolent systemic mastocytosis is the largest unmet need in the Blueprint portfolio for cross-border coordination. Estimates place global prevalence at five to thirteen per 100,000, but diagnostic rates outside high-resource jurisdictions are far below true prevalence because the symptom cluster (chronic urticaria, anaphylaxis, gastrointestinal symptoms, bone pain, cognitive fog) is non-specific. Patients with a tryptase test confirmed pathologically elevated and a KIT D816V mutation confirmed by sensitive PCR routinely have no local treatment option because Ayvakit is not yet approved or reimbursed in their jurisdiction. Outside the United States and parts of the European Union, the indolent SM indication has lagged regulatory adoption by 18 to 36 months in most markets we serve.

GIST patients with PDGFRA exon 18 (D842V) mutations are a separate ultra-rare subgroup. The mutation is typically resistant to imatinib and other standard tyrosine kinase inhibitors, and avapritinib is the only targeted option with meaningful response rates. Confirmed-mutation patients in the GCC, India, and Southeast Asia routinely route through cross-border NPP. Patient profile is typically: confirmed PDGFRA exon 18 mutation by next-generation sequencing performed at a recognised molecular pathology center; progression on prior tyrosine kinase inhibitor therapy or treatment-naive status; and ability to maintain ongoing oral therapy at the standard dosing schedule.

Common cross-border destinations

The highest-frequency NPP destinations for Blueprint products from US-approved inventory are the United Arab Emirates, Saudi Arabia, India, Qatar, and Turkey. Major mast cell disease and GIST referral centers in Dubai, Abu Dhabi, Riyadh, Mumbai, Hyderabad, and Istanbul are common entry points.

Manufacturer engagement posture

Reserve Meds coordinates Blueprint-sourced US commercial product through DSCSA-compliant US specialty distributors. We are not affiliated with, owned by, or contracted as a distributor of Blueprint Medicines. Our role is patient-facing coordination on behalf of named individual patients with a verified prescription. For Blueprint medical affairs or commercial teams interested in cross-border NPP pathways, our BD contact is [email protected].

What Reserve Meds provides

For each Blueprint product request, Reserve Meds coordinates: prescription verification with the treating physician (hematologist, oncologist, or allergist-immunologist depending on indication); biomarker documentation review including KIT D816V testing for systemic mastocytosis and PDGFRA exon 18 sequencing for GIST; DSCSA serialized chain-of-custody from Blueprint through licensed US wholesalers to the named patient; ambient shipping per product specification; destination-country regulatory documentation for Ministry of Health named-patient approvals and customs clearance; and a dedicated coordinator from prescription to delivery.

Clinical governance and prescription review

Every prescription for a product on this page is reviewed by a US-licensed pharmacist before dispensing. Reserve Meds does not substitute generic equivalents for branded specialty products without an explicit prescriber instruction, and we do not dispense any product whose chain-of-custody we cannot serialize back to the FDA-authorised manufacturer or its licensed wholesale partner. Our clinical review confirms indication-on-label appropriateness based on the documentation submitted by the treating physician, identifies any standard drug-drug interaction or contraindication concerns, and confirms that the requested dose, dosing schedule, and dosage form match the prescription. Where the prescription is unclear or where the indication on the prescription is off-label, our pharmacist contacts the prescriber directly. We do not provide medical advice to patients beyond drug-information counseling at dispensing.

Supply chain integrity

Supply integrity is the foundation of Reserve Meds operations. Every shipment carries a serialized DSCSA pedigree document confirming the chain of ownership from the FDA-registered manufacturer or its authorised distributor through a licensed US wholesale distributor to Reserve Meds and onward to the named patient. We do not source through parallel-import channels, third-country re-import, or unverified online wholesale markets. Cold-chain shipments are packed in qualified shippers with temperature data-loggers reading and logging temperature throughout the journey; data-logger reads are reviewed on arrival, and any out-of-specification excursion triggers our quality-hold protocol. For frozen products such as gene therapies and certain antibody-drug conjugates, we use validated frozen-shipper systems with dry-ice replenishment as required.

Destination-country regulatory pathways

Cross-border named patient access operates under jurisdiction-specific regulatory frameworks. In the United Arab Emirates, the Ministry of Health and Prevention (MOHAP) and Dubai Health Authority operate import-permit pathways for unregistered or restricted medicines on a named-patient basis. Saudi Arabia, Qatar, Kuwait, Bahrain, and Oman each operate analogous Ministry of Health named-patient frameworks with country-specific documentation requirements. India operates a personal-import pathway under the Drugs and Cosmetics Rules for quantities consistent with personal therapeutic use, typically up to three months supply per shipment. Turkey, Egypt, Jordan, Lebanon, and Morocco each operate distinct named-patient or import-permit pathways. Reserve Meds maintains current regulatory intelligence for each of these jurisdictions and prepares the documentation package required for each shipment.

What to expect through the coordination process

Patients beginning a request receive an initial coordinator contact within one business day of submission. The coordinator reviews the prescription, identifies the documentation required for the destination country, and provides an indicative cost range. Once required documents are uploaded - prescription, prescriber license verification, patient identification, and any indication-specific documentation such as genetic test results or biomarker reports - we issue a firm quote inclusive of product cost, packaging, shipping, regulatory documentation, and our coordination fee. Patients confirm acceptance of the firm quote before any sourcing or shipping is initiated, and Reserve Meds does not collect any deposit at intake. Once the firm quote is accepted and payment is received, the coordinator initiates sourcing through our licensed wholesale partners and prepares the destination-country regulatory package. Typical end-to-end timing from accepted quote to delivery is two to four weeks for ambient-shipped products and three to five weeks for cold-chain shipments, with variability driven by destination-country customs and regulatory turnaround times.

Not affiliated with the manufacturer

Reserve Meds is an independent operator of named patient program coordination. We are not a subsidiary, affiliate, authorised distributor, or licensed representative of any pharmaceutical manufacturer, and no statement on this page should be read as a partnership, endorsement, or representation by the named manufacturer. Trade names and product references on this page are used for informational purposes to identify the FDA-approved products that Reserve Meds coordinates through US specialty wholesale channels on behalf of named individual patients.

Privacy and data handling

Patient data submitted to Reserve Meds is handled under our HIPAA-aligned privacy policy and our destination-country data protection commitments. We minimise data collection to what is necessary for prescription verification, regulatory documentation, and shipping logistics. Patient identifiable information is shared with US wholesalers, destination-country regulatory authorities, and shipping carriers only as required to complete the coordination, and is not used for any marketing purpose.

Next step for patients

Patients with a confirmed systemic mastocytosis or PDGFRA exon 18 GIST diagnosis and a treating-physician prescription for Ayvakit can begin a request now. Start an Ayvakit request ›

Next step for Blueprint Medicines teams

Blueprint Medicines medical affairs or commercial teams interested in cross-border NPP coordination for non-US territories can reach our BD team at [email protected].

Reserved for you.